FDA Approved: TYKERB — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for TYKERB (lapatinib) from Novartis Pharmaceuticals Corporation to update its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tykerb (lapatinib)

Snippet

SUPPL AP for TYKERB (LAPATINIB)